

# Nucleophile responsive charge-reversing polycations for pDNA transfection

Reece W. Lewis<sup>a\*</sup>, Aswin Muralidharan<sup>abc</sup>, Benjamin Klemm<sup>a</sup>, Pouyan E. Boukany<sup>a</sup>, Rienk Eelkema<sup>a\*</sup>

<sup>a</sup>Department of Chemical Engineering, Delft University of Technology, 2629 HZ Delft, The Netherlands.

<sup>b</sup>Department of Bionanoscience, Delft University of Technology, 2629 HZ Delft, The Netherlands.

<sup>c</sup>Kavli Institute of Nanoscience, Delft University of Technology, 2629 HZ Delft, The Netherlands.

\* Correspondence to: R.W.Lewis@tudelft.nl; R.Eelkema@tudelft.nl

## Abstract

Polycationic carriers promise low cost and scalable gene therapy treatments, however inefficient intracellular unpacking of the genetic cargo has limited transfection efficiency. Charge-reversing polycations, which transition from cationic to neutral or negative charge, can offer targeted intracellular DNA release. We describe a new class of charge-reversing polycation which undergoes a cationic-to-neutral conversion by a reaction with cellular nucleophiles. The deionization reaction is relatively slow with primary amines, and much faster with thiols. In mammalian cells, the intracellular environment has elevated concentrations of amino acids (~10x) and the thiol glutathione (~1000x). We propose this allows for decationization of the polymeric carrier slowly in the extracellular space and then rapidly in the intracellular milieu for DNA release. We demonstrate that in a lipopolyplex formulation this leads to both improved transfection and reduced cytotoxicity when compared to a non-responsive polycationic control.

## Introduction

Gene therapy holds great promise as a treatment for genetic diseases such as cancer, cardiovascular disease, cystic fibrosis and arthritis.<sup>1</sup> These treatments require nucleic acid cargo to reach the intracellular milieu, and in the case of plasmid DNA (pDNA), the nucleus. A carrier or vector is used to protect the cargo from serum nucleases and facilitate uptake into the cell.<sup>2</sup> Viral vectors are generally the most efficacious in terms of transfection, however they suffer from high cost, specialised production and safety concerns around insertional mutagenesis and immune responses.<sup>3</sup> This has promoted the study of nonviral vectors such as cationic polymers, which promise low pathogenicity and cheap scalable production.<sup>4, 5</sup>


Cationic polymers can electrostatically bind to negatively charged nucleic acids, resulting in the formation of nanoparticle complexes. These are typically termed polyplexes when the polycation is a homopolymer, while block copolymers with a neutral, water-soluble block yield polyplex micelles, which have a protective corona.<sup>2, 6</sup> This corona typically conveys polyplex micelles with improved extracellular stability, however it can also reduce cellular internalisation, leading to poor transfection.<sup>7</sup> An alternative is to coat polyplexes with lipids to form lipopolyplexes, combining favourable characteristics from polyplexes (facilitated endosomal release and nucleus entry) and lipid complexes (improved cytotoxicity and cellular uptake).<sup>8-13</sup>

Polyplex performance can be tuned by varying the ratio of positive charges on the polycation to negative charges on the nucleic acid.<sup>5</sup> An excess of cationic charge is typically used to achieve sufficient DNA packaging and cellular entry, however this can limit complex dissociation once inside the cell, resulting in poor transcription efficiency.<sup>4, 14, 15</sup> Additionally, highly cationic polyplexes are often cytotoxic, since cationic polymers can damage cell membranes.<sup>2, 12</sup> This has motivated the development of charge-reversing polycations which are

able to transition from cationic to neutral or negative charge, either gradually through hydrolysis at physiological pH,<sup>15-18</sup> or in response to intracellular signals such as reactive oxygen species (ROS),<sup>7, 19</sup> and esterases.<sup>20, 21</sup> For example, Zhu et. al reported reduced cytotoxicity and improved in vitro luciferase expression for their ROS responsive polysulfonium polyplexes when compared to permanently cationic controls.<sup>19</sup> We note, however, that many of these systems are either relatively non-specific for the intracellular environment (hydrolysis), or rely on signals which are mainly elevated inside cancerous cells, limiting scope of application.

Thiol/amine nucleophiles (S/N), which can be found in a wide range of biomolecules with typically elevated intracellular concentrations, are until now an unexplored class of charge-reversing signal. We were inspired to investigate nucleophile responsive polycations after our recent work demonstrating controlled (de)cationization of polyvinylpyridine (PVP) copolymers by successive additions of an allyl acetate (ionization), and S/N- nucleophiles (deionization).<sup>22, 23</sup> With an appropriate polyanion, the PVP copolymers (dis)assembled into coacervate core micelles, effectively achieving signal controlled polyanion encapsulation and release.<sup>24</sup> Importantly, we found that the decationization reaction is significantly faster for thiols compared to primary amines (**Figure 1a**). We therefore hypothesised that the responsive cationic PVP could be applied as a two-stage charge-reversing polymer within polyplexes.

The first stage would occur extracellularly, where amine moieties on free amino acids (~3 mM in human blood plasma),<sup>25, 26</sup> could be exploited to slowly reduce cationic charge, leading to reduced extracellular cytotoxicity. Once inside the cell, the second stage can begin where an elevated concentration of amino acids (~50 mM)<sup>27, 28</sup> and the thiol glutathione (GSH, 1 – 10 mM in cytosol and 2 - 20  $\mu$ M extracellularly),<sup>3, 29</sup> could be used to trigger an accelerated decationization and release of pDNA for transfection (**Figure 1c**).



**Figure 1:** Outline of nucleophile responsive charge-reversing polycation study. a) General structure of responsive polycation and its charge-reversing reaction with S/N- nucleophiles. Representative <sup>1</sup>H NMR conversion data for the decationization reaction in phosphate buffer (pH 7.4, 100 mM) at RT ([cationic units]=[nucleophile] = 7 mM), see *Figures S1-S2* for additional data. Curves are fit with pseudo first-order kinetic model. b) General structure of non-responsive polycation. c) Scheme showing proposed two-stage charge reversing process of responsive pDNA complexes in extracellular and intracellular conditions. \*In this work cellular transfection is demonstrated by combining the polymer complexes with a lipid.

## Methods

### *Materials*

N,N-dimethylacrylamide (DMA, 99%) and 4-vinylpyridine (4VP, 95%) were obtained from Sigma Aldrich and passed through basic alumina prior to use to remove inhibitor. 2-(dodecylthiocarbonothioylthio)-2-methylpropionic acid (DDMAT, 98%), 4-(((2-carboxyethyl)thio)carbonothioyl)thio)-4-cyanopentanoic acid (CETCPA, 95%, ABCR), 7-diethylamino-3-[N-(3-maleimidopropyl)carbamoyl]coumarin (coumarin maleimide, 97%), bovine serum albumin (BSA,  $\geq 96\%$ ), butyl bromide (BuBr, 99%), HAMS F-12 no L-glutamine, no phenol red (Bio-technie), L-buthionine sulfoximine (BSO), L-Glutathione reduced (GSH, 98%), L-Threonine (Thr,  $\geq 98\%$ ) were all used as received and purchased from Merck / Sigma Aldrich unless stated otherwise.  $\text{CDCl}_3$  (99.8% D),  $\text{D}_2\text{O}$  (99.96% D),  $\text{d}_8$ -THF (99.5% D) were obtained from Eurisotop. Diethyl( $\alpha$ -acetoxymethyl) vinylphosphonate (DVP) was synthesised according to our previous work.<sup>22</sup>

The lipids 1,2-dioleoyl-*sn*-glycero-3-phosphoethanolamine (DOPE) and 3 $\beta$ -[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol hydrochloride (DC-Chol) were purchased from Avanti Polar Lipids Company. Nutrient Mixture Ham's F-12 (Sigma Aldrich), fetal bovine serum (FBS, Sigma Aldrich) and 0.25% Trypsin-EDTA (Gibco) were used as received. pEGFP-C1 plasmid (4.7 kb) was amplified with competent *E. coli* cells (Invitrogen™ Subcloning Efficiency™ DH5 $\alpha$  Competent Cells), transformed using the heat shock method. After transformation, the cells were cultured overnight in LB broth w/ Kanamycin and then the plasmids were harvested using the GeneJET plasmid mini prep kit.

### *NMR spectroscopy*

$^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectra were recorded on an Agilent 400-MR DD2 spectrometer (399.7 and 100.5 MHz, respectively).

### *Gel permeation chromatography (GPC)*

The average molecular weight and dispersity ( $\text{Đ}$ ) of the synthesized polymers was measured using a Shimadzu GPC with DMF LiBr (25 mM) as eluent with a flow rate of 1.0 mL/min at 50°C. The system was equipped with a Shimadzu RID-10A refractive index detector, a Shimadzu SPD-20A UV-Vis detector, PLgel guard column (MIXED, 5  $\mu\text{m}$ ; 50 mm x 7.5 mm), and Agilent PLGel column (MIXED-C, 5  $\mu\text{m}$ ; 300 mm x 7.5 mm), providing an effective molar

mass range of 200 to  $2 \times 10^6$  g/mol. The GPC columns were calibrated with low dispersity PMMA standards (Sigma Aldrich) ranging from 800 to  $2.2 \times 10^6$  g/mol, and molar masses are reported as PMMA equivalents. A 3rd-order polynomial was used to fit the log  $M_p$  vs. time calibration curve, which was near linear across the molar mass ranges.

### ***Dynamic Light Scattering (DLS)***

Hydrodynamic diameters were evaluated using cumulant method on a Malvern Zetasizer Nano ZS employing a 633 nm laser at a back-scattering angle of  $173^\circ$ . Sizes are reported as intensity weighted harmonic mean size (Z-average diameter), with each data point from 10 runs of 5 seconds. Zeta potential measurements were conducted in folded capillary zeta cells (Malvern, DTS1070). Each zeta potential data point was from 2 or 3 measurements of a minimum of 10 runs. For pDNA release studies the temperature inside the cell was set to  $37^\circ\text{C}$  (all other studies at  $25^\circ\text{C}$ ).

### ***Transmission electron microscopy (TEM)***

TEM measurements were performed on a JEOL JEM-1400plus TEM operated at 120 kV. Samples were prepared by placing 3  $\mu\text{L}$  of the solution onto carbon coated copper grids and incubating for 1 minute followed by blotting the excess solution onto filter paper. The samples were then washed (2x) with of milli-q water, followed by removing the excess onto filter paper. For stained samples, uranyl acetate (UA) solution (3  $\mu\text{L}$ , 2% (w/v)) was applied for 30 seconds before removing the excess onto filter paper. Images were analysed using Image J software by manually measuring the length of the longest dimension across 3 images ( $n \geq 30$ ). Values are reported as mean  $\pm$  SD.

### ***Gel electrophoresis***

1% agarose (Promega) gels mixed with 0.01% SYBR Safe were prepared in TAE buffer. SYBR Safe can bind to exposed DNA and emit a fluorescence signal. The samples (10  $\mu\text{L}$ ) were first mixed with 6x DNA loading dye (1.2  $\mu\text{L}$ , thermofisher) and loaded into wells prepared in the agarose gel. A voltage drop of 100 V was applied for a duration of 45 minutes in a Mupid One Advance electrophoresis system. The gels were then imaged in a gel imager (BIO-Rad Gel Doc XR+) with Image Lab software.

### ***Polyvinylpyridine (block-co)polymer synthesis***

1. DDMAT (97 mg, 0.27 mmol), 4VP (3.36 g, 32 mmol), and ethanol (4.5 mL) were combined in a glass tube sealed with rubber septum. The reaction mixture was deoxygenated by bubbling

with argon for 30 minutes and placed into a LED reactor (444 nm, see previous work for set up details).<sup>24</sup> The reaction was quenched after 11 h irradiation (71% conversion by <sup>1</sup>H NMR spectroscopy,  $M_{n,conv} = 9.2$  kDa) by removing the glass tube from the light source and opening to air. The polymer was then precipitated into hexane and dried in a vacuum oven overnight (50°C) to 1.84 g yellow solid (**1**).

The polyvinylpyridine block co-polymer (**2**) was prepared in a two-step process starting with the synthesis of a water-soluble macro-CTA (**pDMA<sub>261</sub>**). For this, CETCPA (82.2 mg, 0.27 mmol), DMA (7.93 g, 80 mmol), DSS (21.3 mg, 0.10 mmol, as internal std) and DI water (11.7 mL) were combined in a glass tube sealed with rubber septum. The reaction mixture was deoxygenated by bubbling with argon for 30 minutes and placed into a LED reactor (444 nm). The reaction was quenched after 2 h irradiation (87% conversion by <sup>1</sup>H NMR spectroscopy,  $M_{n,conv} = 26.2$  kDa) by removing the glass tube from the light source and opening to air. The polymer was then purified by dialysis (MWCO 500 – 1000 Da), followed by freeze-drying to obtain 6.2 g of a light-yellow powder (**pDMA<sub>261</sub>**).

**2.** **pDMA<sub>261</sub>** (1.86 g, 0.071 mmol), 4VP (1.22 g, 11.6 mmol), DSS (8.5 mg, 0.039 mmol, as internal std) and MeOH (5 mL) were combined in a clear glass tube and deoxygenated by bubbling with argon for 15 minutes. The tube was then placed into a LED reactor (444 nm). The reaction was quenched after 29 h irradiation (64% conversion of 4VP by <sup>1</sup>H NMR spectroscopy,  $M_{n,conv} = 37.2$  kDa) by removing the glass tube from the light source and opening to air. The polymer was then diluted with methanol and twice precipitated into diethyl ether (250 mL). Lastly, the precipitate was dissolved in DI water/ethanol (50/50) and dialysed against DI water (MWCO 500 – 1000 Da). After freeze-drying, 1.05 g of a white powder (**2**) was obtained.

All polymers were analysed by GPC (DMF, LiBr 25 mM), with low to moderate dispersities ( $\mathcal{D} \leq 1.35$ ). Successful chain extension for **2** from **pDMA<sub>261</sub>** was supported by a shift of a single peak from 28.5 kDa to 30.0 kDa (*Table S1* and *Figure S14*).

Coumarin maleimide labelled polycations were prepared using a modified one-pot aminolysis/thiol-ene procedure (full details in SI).<sup>30</sup> Cy5 labelled **1** (**1c**) was prepared using an azide functionalised allyl derivative and subsequently functionalising with Cy5-alkyne via Cu catalysed click (full details in SI).



### ***Polyvinylpyridine (block-co)polymer ionization***

To prepare the polycations used in this work **1** and **2** were reacted with either DVP (~1 eq.) in D<sub>2</sub>O at room temperature for 2 - 3 days to yield **1a** and **2a**, or BuBr (~10 eq.) in MeOH at 65°C for ~20 h to yield **1b** and **2b**. The polymers were then purified by a combination of precipitation into diethyl ether and dialysis against 100 mM NaCl and DI water. Full synthetic procedures are in SI.

### ***Polymer titration study***

Throughout this work 10 mM pH 7.4 phosphate buffer is widely used and abbreviated to PB. Stock solutions of all polycations (**1a**, **1b**, **2a**, **2b**) were prepared in PB at concentrations ranging from 2 – 20 mM (cationic units). Increasing amounts of each polycation were then added to pDNA (650 ng) in 0.97 mL PB. These additions corresponded to N/P from 0.5 to 16 (ratio of cationic nitrogens in polymer to anionic phosphates in pDNA). Total volume of polycation addition was < 50  $\mu$ L to keep concentration of pDNA approximately constant (0.65  $\mu$ g/mL). Results are presented as means  $\pm$  SD (3 measurements on each sample, ran in duplicate).

### ***Micelle and Polyplex preparation***

Stock solutions of all polycations were prepared in PB to concentrations as required for the N/P of the complex (typically 6 mM polycationic units). For all experiments pDNA complexes were prepared fresh (used within day). pDNA (typically 400  $\mu$ g/mL, 10 mM Tris-HCl, pH 8.5 buffer), polycation and PB were combined and shaken in 1.5 mL Eppendorf tubes (final pDNA concentration = 65 ng/ $\mu$ L). These were then briefly centrifuged to ensure full mixing of the solutions at the bottom of the tube. The complexes were incubated at room temperature for 30 mins before characterisation or use. For size analysis, complexes were diluted to 6.5 ng/ $\mu$ L (pDNA) just before analysis, with data presented means  $\pm$  SD (n = 3).

### ***Lipid and lipopolyplex preparation***

The lipid DOPE/DC-Chol (70/30) was prepared according to manufacturer's instructions (Avanti). Specifically, stock solutions of DOPE and DC-Chol were prepared in chloroform, these were then combined to yield a solution of DOPE and DC-Chol at a 70/30 wt%. The chloroform was evaporated (rotary evaporation) forming a thin lipid film. The film was dissolved in DI water (sonication 5 – 10 minutes) at a concentration of 4 mM total lipid. The

solution was passed through a 0.22  $\mu\text{m}$  filter to sterilise. The size of the lipids in DI water was measured as  $91 \pm 9.8$  nm using DLS.

The lipid solution was then added to the desired polyplex at an L/P (lipid/pDNA) mass ratio of 10:1. This was then diluted with PB to a final pDNA concentration of 32.5 ng/ $\mu\text{L}$ . These were then briefly centrifuged and incubated at room temperature for 30 mins before characterisation or use. For size analysis, complexes were diluted to 6.5 ng/ $\mu\text{L}$  (pDNA) just before analysis, with data presented means  $\pm$  SD ( $n = 3$ ). The lipid complex (Lipid) was prepared as above without the addition of a polycation and cell culture medium used as diluent rather than PB. Note: the use of cell culture medium is important, as lipid complexes prepared in PB transfected poorly (similar to naked pDNA).

### ***pDNA release studies***

Polyplexes and micelles were prepared (65 ng pDNA / $\mu\text{L}$ ) then diluted into either HAMS-F12 (phenol red free), 1 mM GSH, 1 mM GSH in HAMS-F12 (phenol red free) (both) or PB to a final concentration of 6.5 ng pDNA / $\mu\text{L}$ . These solutions were maintained at 37°C for up to 24 h, with their zeta potential and size measured at specified time points. For gel electrophoresis measurements samples were taken at 1 and 4 hours and loaded into gels within 30 minutes of sampling.

### ***Cell culture***

Chinese Hamster Ovaries cells, CHO-K1 (DSMZ) were cultured in HAMS-F12 medium (Gibco) containing 10% FBS (cell culture medium). Cells were cultured in a humidified atmosphere of 5%  $\text{CO}_2$  at 37°C. Cells were passaged every 3 to 4 days up to passage 16. Detailed procedures are given in the SI.

### ***Statistical analysis***

For flow cytometry data where tests of significance are given, a two-tailed unpaired Students t-test was applied.  $P < 0.05$  was regarded as statistically significant.

## **Results and Discussion**

### ***Formation of pDNA complexes***


To study the transfection capability of nucleophile responsive cationic PVPs, polymers with architectures capable of forming both polyplex and micelle pDNA complexes were prepared

by RAFT polymerisation (**Figure 2a**). For this, a 4-vinyl pyridine homopolymer (**1**, p4VP<sub>85</sub>) and block-copolymer (**2**, pDMA<sub>261</sub>-b-4VP<sub>104</sub>) were synthesised. In both cases, GPC peaks were monomodal, with molecular weights determined by <sup>1</sup>H NMR conversion and GPC in reasonable agreement (**1**:  $M_{n,NMR} = 9.2$  kDa,  $M_{n,GPC} = 5.3$  kDa,  $D = 1.34$ ; **2**  $M_{n,NMR} = 37.2$  kDa,  $M_{n,GPC} = 30.0$  kDa,  $D = 1.30$ ). These polymers were then ionized by reaction with diethyl( $\alpha$ -acetoxymethyl) vinylphosphonate (DVP), leading to the desired responsive cationic PVPs (**1a** and **2a**, respectively, chemical structures shown in **Figure 1a**). A matching set of non-responsive and permanently cationic control polymers were prepared by reaction with BuBr (**1b** and **2b**, **Figure 1a**). The conjugate acid pK<sub>a</sub> of vinyl pyridine is 4.9,<sup>31</sup> so any unreacted pyridine residues are assumed to be neutral at physiological pH (7.4). Both sets of polycations were dialysed against 0.1 M NaCl and then DI water to yield polycations with a chloride counterion. Note that without this step the responsive polycations are unstable during freeze-drying (*Figure S3*).

We then combined these polycations with pDNA (pEGFP-C1, 4.7 kbp) and studied their complex formation as a function of N/P, defined here as the ratio of cationic nitrogens (N) to anionic phosphates (P) (**Figure 2b-c**). With increasing N/P, the zeta potential increased from negative values for pure pDNA ( $-25 \pm 7$  mV) to positive values, plateauing around 14 and 17 mV for **1a** and **1b**, indicating the formation of polyplexes with a net positive surface charge. Complexes from the block copolymers **2a** and **2b** recorded near neutral zeta potentials (0 and 3 mV) due to their micelle forming neutral block dominating the surface charge. Encapsulation of pDNA appears complete at  $N/P \geq 2$  for all polymers, a conclusion supported by retention of samples to the baseline for  $N/P \geq 2$  during gel electrophoresis (*Figure S4*).

Lastly, we studied the size and morphology of the pDNA complexes ( $N/P = 4$ ) by both dynamic light scattering (DLS) and transmission electron microscopy (TEM, **Figure 2d-e**). The responsive polyplex **1a-4** (pDNA complex designation: polymer number-N/P ratio) consisted

of a mixture of spherical and short wormlike species, while the control polyplex **1b-4** was typically spherical. The pDNA micelle complexes **2a-4** and **2b-4** formed a mixture of wormlike and ring species, as is expected for cationic block-copolymer pDNA complexes.<sup>4</sup> Thus, the presence of worms for **1a-4** may be due to the phosphodiester terminus of the responsive cationic moiety acting as a water interfacing group. The size of pDNA complexes was typically in the 100 – 250 nm range, with good agreement between DLS and TEM. In the case of **1b-4**, however, the DLS diameter (1.44  $\mu\text{m}$ ) was found to be 10-fold larger than that observed from TEM (139 nm). We note that this disparity is most likely due to a numerically small amount of large ( $>1\ \mu\text{m}$ ) species dominating the DLS measurement (*Figure S6*).



**Figure 2.** Preparation of polycations and their pDNA (pEGFP-C1) complexes. a) Preparation of polyamines by RAFT polymerisation followed by their reaction with electrophiles to generate either responsive or permanently cationic (control) polycations. b) Formation of micelle and polyplex type pDNA complexes studied in this work. c) Titration of polycations to pDNA (6.5  $\mu\text{g/mL}$  pDNA; 20  $\mu\text{M}$  phosphates) as a function of N/P (prepared in 10 mM pH 7.4 phosphate buffer). d) Summary of N/P = 4 pDNA complex size. Diameters are reported as

the average across 3 samples (DLS) or 3 images (TEM)  $\pm$  SD. For TEM, diameter is the length of the longest dimension. e) TEM images of N/P = 4 pDNA complexes (stained, 2 wt% uranyl acetate), scale bar 200 nm. Additional characterisation data can be found in *Figures S4 – 14* (gel electrophoresis, polymer characterisation and additional DLS/TEM data).

### ***Intracellular and extracellular release***

After forming polyplex and micelle pDNA complexes, we investigated their rate of decomplexation and pDNA release in conditions simulating the intra- and extra-cellular environment (**Figure 3a**). Estimates for the concentration of free amino acids in human plasma range from 2.3 – 3.1 mM,<sup>25, 26, 32</sup> while the concentration of GSH is typically only 2 – 20  $\mu$ M.<sup>3,</sup><sup>29</sup> Thus, we selected serum free HAMS-F12 cell culture media (CCM) as an extracellular model, with an amino acid concentration of 3.8 mM. We note that in CCM a range of nucleophiles are present (4.7 mM RNH<sub>2</sub>, 0.3 mM R<sub>2</sub>NH and 0.2 mM RSH), all of which may be able to trigger the de-ionization reaction. The mammalian intracellular environment consists of an elevated concentration of both amino acids ( $\sim$ 50 mM)<sup>27, 28</sup> and GSH (1 – 10 mM).<sup>3, 29</sup> Given the known high reactivity of the responsive polycations towards thiols, we selected 1.0 mM GSH as a simple and conservative model. This approach also allows for a clearer understanding around the role of GSH compared to amino acids.


We studied the de-ionization process at 37°C by both zeta potential (ZP) and gel electrophoresis across 4 h. Control complexes were found to be stable in both CCM and 1 mM GSH by gel electrophoresis, as expected (*Figure S15*). Interestingly, a reduction in zeta potential to near neutral values was typically observed for the control complexes, likely due to adsorption of ions from the media (**Figure 3**, red data points).

Promisingly, the responsive complexes (**Figure 3**, blue data points) yielded greater reductions in ZP for all conditions, indicating loss of cationic charge. The rate of this loss is dependent on the media, complex morphology and N/P; with low N/P polyplexes in 1 mM GSH giving the most rapid response. For example, the responsive polyplex **1a-4** recorded a gradual reduction in ZP over 4 h in CCM from -2 to -24 mV (**Figure 3b**), indicating approximately complete pDNA release (ZP = -17 mV for pDNA only in CCM). In 1 mM GSH a significantly faster release was observed, with ZP reducing from +14 to -25 mV in 15 minutes (ZP = -24 mV for pDNA only in 1 mM GSH). This demonstrates a 16 times faster release of pDNA in model intracellular conditions compared to extracellular conditions for **1a-4**. These conclusions were supported by gel electrophoresis, with complete release observed within 4 h and 1 h for CCM and 1 mM GSH, respectively (**Figure 3c**).

Increasing N/P to 16 (**1a-16**) resulted in a quite similar ZP decrease in CCM, albeit starting at a more positive value (from +3.3 to -18 mV in 4 h). Interestingly, in GSH the ZP drop to -24 mV was approximately 8 times slower compared to the N/P = 4 polyplex, suggesting a significantly slower decationization and pDNA release. Note, however, that at N/P = 16 the molar excess of nucleophilic species to responsive cationic units is reduced to approximately 3 in GSH (from 12 for N/P = 4), while in CCM the excess remains greater than 10 for all N/P. Thus, the difference may at least partly be due to a reduced nucleophile excess in our model closed system.

For the micelle complexes in CCM, little change in ZP was observed over 4 h for both **2a-4** (from -0.7 to -2.1 mV) and **2a-16** (from -0.3 to -2.2 mV, **Figure 3d**). To probe a possible longer release profile, an additional measurement was taken at 24 h, which recorded a significantly greater reduction for both **2a-4** (-7.1 mV) and **2a-16** (-12.5 mV). While this suggests pDNA release in the order of 24 h, gel electrophoresis measurements on **2a-4** identified release within 4 h. It is worth noting that the expected product after responsive micelle deionization (**2**) shifts

ZP values measured for pDNA closer to zero (*Table S2*). This does complicate interpretation of the ZP data, therefore the release timeframe can likely only be estimated as being between 4 and 24 h. In 1 mM GSH, the responsive micelles were similarly found to deionize slower than their polyplex counterparts. Here, however, a reduction in ZP was already clear after 4 h and gel electrophoresis measurements indicated a partial pDNA release after only 1 h (**Figure 3e**).



**Figure 3.** Decationization and pDNA release studies under model intra- and extra-cellular conditions. Samples were maintained at 37°C and the concentration of pDNA (as anionic phosphates) was maintained at 0.02 mM for zeta potential (ZP) measurements and 0.06 mM for gel electrophoresis. a) Expected responsive complex pDNA release under model extracellular (HAMS-F12 media, CCM) and intracellular (1.0 mM GSH) conditions. b) Change in ZP over time for responsive (blue) and non-responsive (red) polyplexes in CCM and 1 mM GSH. c) Gel electrophoresis measurements of **1a-4** after incubation in CCM or 1 mM GSH for 1 and 4 h. d) Change in ZP over time for responsive (blue) and non-responsive (red) micelles

in CCM and 1 mM GSH. e) Gel electrophoresis measurements of **2a-4** after incubation in CCM or 1 mM GSH for 1 and 4 h. Additional gel electrophoresis data in *Figures S15-S16*.

### ***Cellular uptake and transfection***


After demonstrating nucleophile triggered pDNA release in both 1 mM GSH and CCM, we investigated the in vitro transfection of EGFP encoding pDNA complexes (N/P = 4 and 16) on Chinese hamster ovary (CHO) cells. Initial studies analysed by confocal laser scanning microscopy (CLSM) indicated poor EGFP transfection for all complexes which was similar to naked pDNA (*Figure S17*). A lipid formulation (DOPE/DC-Chol: 70/30) was as used as a positive control, enabling a normalised fluorescence to be evaluated. The best performing complex was the non-responsive polyplex **1b-16**, with a normalised fluorescence (GFP) of 0.08, however the cells were visually rounded up and shrunken. In addition, cell numbers appeared low for this formulation suggesting most of cells were detached and non-viable due to the large polycation excess (*Figure S18*).

To improve transfection performance, we prepared lipopolyplexes from both the responsive and control polyplexes at a mass ratio of lipid:pDNA = 10:1 (**Figure 4a**). Again, the lipid mixture of DC-Chol/DOPE (70/30) was used, as has already been successfully applied in lipopolyplex preparations.<sup>20</sup> The lipopolyplexes (N/P = 4) were characterised by DLS, yielding a size of  $334 \pm 9$  nm for the responsive lipopolyplex (**L1a-4**) and  $2.45 \pm 1.8$   $\mu$ m for the control lipopolyplex (**L1b-4**). The complexes were positively charged, with ZP values of 15.4 mV (**L1a-4**) and 16.9 mV (**L1b-4**). TEM images revealed the formation of layered or walled structures, which tended to aggregate under TEM imaging conditions (*Figure S21*). Promisingly, CHO cells treated with **L1a-4** had a noticeable increase in EGFP expression with normalised GFP fluorescence more 7 times larger than its control lipopolyplex (**L1b-4**, **Figure 4b**).



With this promising result we investigated the cellular uptake of polycation and pDNA for all complexes to understand if cellular internalisation was limiting, particularly for the **1b-4** and **L1b-4** complexes, which have a noticeably larger diameter (DLS) than the other complexes. We prepared coumarin end-functionalised derivatives of our synthesised polycations (*Scheme S1*) and combined them with Cy3 labelled pDNA. The extent of pDNA and polymer internalisation in CHO cells was then evaluated 4 h after treatment using CLSM (**Figure 4b** and *Figure S19*). Uptake of pDNA was found to be similar for all complexes except **2a-4**, which internalised poorly. Importantly, **L1a-4** and **L1b-4** had normalised Cy3 fluorescence values within 10% of each other, indicating that the observed difference in transfection is not due to poor pDNA cellular entry with the control complex. A similar uptake pattern was observed for the polycations (coumarin fluorescence), as expected for complexed species (*Figure S20*). We also note that **L1a-4** had only 19% larger Cy3 fluorescence than **1a-4** despite the more than 16 times increase in EGFP expression. A plausible explanation may be that the polyplex (and micelle) carriers have poor endosome escape, which is overcome in lipopolyplexes where lipids such as DOPE are known to assist.<sup>8, 33</sup>

To better quantitate the relative performance of the responsive and control lipopolyplexes, an extensive transfection study was analysed by flow cytometry (**Figure 4c**). Lipopolyplexes were prepared at N/P values ranging from 2 to 16, with the control lipopolyplexes offering no significant improvement (NS:  $p > 0.05$ ) over cells treated with pDNA alone for all N/Ps except 16. Importantly, the responsive lipopolyplexes either significantly outperformed (N/P = 2,4,8) or matched (N/P = 16) their control counterparts. At N/P = 4 the greatest improvement was observed, with a GFP mean fluorescence intensity (MFI) 10 times greater than its control and a MFI that was insignificantly different from the lipid.



**Figure 4.** Lipopolyplex preparation, EGFP transfection and pDNA localisation data. a) Preparation and particle characterisation of responsive and control lipopolyplexes (lipid:pDNA = 10:1 w/w). Lipopolyplexes are composed of aggregates (main TEM image, scale bar 2  $\mu$ m) of smaller sub-species (inset image, scale bar 200 nm). b) Normalized fluorescence intensity of CHO cells treated with various pDNA (1  $\mu$ g/well) complexes as measured by CLSM. GFP fluorescence measured 48 h after treatment and Cy3 fluorescence (from Cy3 labelled pDNA,  $\lambda_{\text{ex}} = 543$  nm,  $\lambda_{\text{det}} = 548 - 797$  nm) measured 4 h after treatment. The results are normalised to a lipid formulation (DOPE/DC-Chol:70/30). c) Mean GFP fluorescence intensity (MFI) of CHO cells 48 h after treatment with control and responsive lipopolyplexes as measured by flow

cytometry ( $n = 5$ , each measurement  $>10k$  cells, error bars are  $\pm$  SD, NS =  $p > 0.05$ , \* =  $p < 0.05$ , \*\* =  $p < 0.01$ ). Additional TEM and CLSM images in *Figures S17 – S21*.

### ***Role of nucleophile responsive polycation***

Such an improvement in transfection performance for the responsive lipopolyplex compared to a permanently cationic control is promising, however it did not outperform its constituent lipid on its own. This clearly limits applications of the current responsive lipopolyplex, however we believe future application of the charge-reversing chemistry in more optimised designs may overcome this. For the purposes of this study, we wish to demonstrate that the improved transfection is not simply due to extracellular deionization of the lipopolyplex into the constituent lipid complex. Specifically, we wanted to show that the responsive polycationic unit reaches the intracellular milieu intact and is then able to undergo deionization to release the bound pDNA.


We began by synthesising a new variant of polymer **1a** (**1c**, **Figure 5a**), with a fraction of the responsive cationic moieties replaced with a Cy5 labelled analogue (see SI for full synthetic details). NMR studies on **1c** indicated similar decationization behaviour to **1a** when exposed to an excess of a model amino acid (threonine, *Figure S29*). Promisingly, cells treated with lipopolyplexes prepared from **1c** (N/P = 4 and 16) had noticeable intracellular Cy5 fluorescence 4 h after treatment (**Figure 5b-c**). To account for any internalisation of the free Cy5 species formed after deionization, a decationized sample of **1c** was prepared by treating it with 5x excess GSH. Cells treated with the decationized **1c** (GSH pre-treat) recorded little Cy5 fluorescence ( $<4\%$  of the corresponding L1c complex), indicating that the free Cy5 moiety internalises poorly. These experiments strongly indicate that the responsive cationic moiety does reach the intracellular milieu intact.

To investigate this further, we ran additional EGFP transfection studies comparing the responsive lipopolyplex **L1a-4** to **L1a-4** which has been pre-treated with 2 mM GSH in CCM

for 1 h at 37°C (GSH pre-treat). This treatment is intended to induce significant ‘extracellular’ deionization. In this way, if the responsive lipopolyplex derives its transfection capability from extracellular degradation, we would expect similar or enhanced transfection performance. Promisingly, we observed a greater than 75% reduction in transfection for the deionized **L1a-4** (GSH pre-treat) compared to non-treated **L1a-4** (control, **Figure 5d**).

After demonstrating internalisation of responsive polycationic functionality, we next studied the role of intracellular GSH. For this, we repeated the EGFP expression study on cells treated with buthionine sulfoximine (BSO), which is known to inhibit GSH production.<sup>34</sup> Surprisingly, BSO treated cells had little change in EGFP expression relative to untreated cells, with only the N/P = 2 lipopolyplex recording a near significant reduction ( $p = 0.11$ ) in expression (**Figure 5e**). To confirm intracellular GSH levels had reduced after BSO treatment, a luciferin based GSH assay was applied. We measured GSH levels immediately after BSO treatment, corresponding to the time when pDNA complexes are added to the cells ( $t = 0$ ), and after a further 48 h, when the cells would be harvested for transfection analysis ( $t = 48$  h). At  $t = 0$ , intracellular GSH for standard culture conditions was found to be within the expected range (4.6 mM), while cells treated with 1 mM BSO had significantly reduced intracellular GSH (below limit of test detection, **Figure 5f**). After 48 h, intracellular GSH was no longer depleted in BSO treated cells, with standard culture ( $3.1 \pm 0.9$  mM) and BSO ( $2.9 \pm 0.3$  mM) recording similar GSH concentrations. This recovery in intracellular GSH clearly limits the conclusions that can be drawn from the 48 h transfection measurements, and thus EGFP expression after only 24 h was studied for the N/P = 4 complex (**Figure 5e**). At 24 h, EGFP expression was significantly reduced compared to 48 h, and while relative GFP fluorescence in standard culture ( $2.9 \pm 0.9$ ) was larger compared to BSO treated cells ( $1.7 \pm 0.9$ ), this difference was again found to be insignificant ( $p = 0.21$ ).

The mismatch of timescales around GSH depletion and EGFP transfection does not allow for definitive conclusions from this experiment. What is most likely, however, is that given the high concentration of intracellular GSH and amino acids (~50 mM), a combination of both trigger polymer decationization and pDNA release. Such a conclusion is also supported by our model pDNA release studies, which demonstrate release within 4 h for both 1.0 mM GSH and 3.8 mM amino acids.




**Figure 5.** Investigations into role of nucleophile responsive polycationic functionality. a) Polymer structure of **1c**, a Cy5 labelled responsive polycation. b) Cy5 (red) localisation study of CHO cells treated with lipopolyplexes prepared using **1c** (**L1c-4**, Control). These are compared to cells treated with matching lipopolyplexes prepared from **1c** pre-treated with 5x excess GSH (**L1c-4**, GSH pre-treat). Images were taken using CLSM with Cy5 ( $\lambda_{\text{ex}} = 633 \text{ nm}$ ,  $\lambda_{\text{det}} = 638 - 797 \text{ nm}$ , red) and bright field channels overlaid, scale bar is 25  $\mu\text{m}$ . c) Normalised Cy5 fluorescence of cells treated with lipopolyplexes prepared from **1c** (Control) and decationized **1c** (GSH pre-treat). d) Normalised EGFP transfection of cells treated with **L1a-4** (Control) compared to **L1a-4** with GSH pre-treatment (2 mM GSH in CCM, 37°C for 1 h). Data is mean  $\pm$  SD ( $n = 3$ ) as evaluated by flow cytometry. e) GFP fluorescence 48 h (or 24 h

where stated) of lipopolyplex treated CHO cells relative to untreated cells under the same culture condition (standard culture or 1 mM BSO). Data is mean  $\pm$  SD ( $n \geq 3$ ) as evaluated by flow cytometry. f) Intracellular GSH concentration of standard culture and BSO treated cells at  $t = 0$  and 48 h. Data is mean  $\pm$  SD ( $n = 4$ ) as measured using a commercial luminescence-based assay which produces luciferase in the presence of GSH (*Figure S27*). \*For  $t = 0$  (1 mM BSO) intracellular GSH was below limit of detection.

### ***Cytotoxicity of polycations and lipopolyplexes***

The in vitro cytotoxicity of the lipopolyplexes and constituent polycations was evaluated via an MTS assay (**Figure 6**). Promisingly, viability for cells treated with responsive lipopolyplexes remained  $\geq 60\%$ , regardless of N/P, while non-responsive lipopolyplexes were notably toxic for  $N/P \geq 8$  (viability  $< 5\%$ ). Cells treated with naked polycations demonstrated a similar trend, with **1b** reducing viability to 0.4% at 0.1 mM (23  $\mu\text{g/mL}$ ). This concentration of **1b** correlates with the concentration of **1b** in wells treated with its  $N/P = 8$  lipopolyplex (0.12 mM), indicating a matching onset of toxicity for both the naked polymer and lipopolyplex. By fitting the data with a sigmoidal model, a near 10 times larger effective concentration of half maximal effect ( $EC_{50}$ ) is obtained for **1a** (0.47 mM) compared to **1b** (0.05 mM). Given that **1a** can be a product in a DVP fuelled chemical reaction network (CRN), we found its good biocompatibility noteworthy and in large contrast to commonly used reagents in typical CRNs.<sup>35-38</sup> We also analysed the toxicity of DVP and found it non-toxic (82% viability) at 0.24 mg/mL (1 mM) (*Figure S30*).



**Figure 6.** In vitro cytotoxicity studies on CHO cells via MTS assay (mean  $\pm$  SD,  $n = 3$ ). Cells were treated with a) lipopolyplexes ( $0.5 \mu\text{g}$  pDNA / well) at various N/P ratios and b) responsive and non-responsive polycations. Data is fitted using sigmoidal four-parameter logistic model, with  $\text{EC}_{50}$  determined as  $0.47 \text{ mM}$  for **1a** and  $0.05 \text{ mM}$  for **1b**, see *Figure S31* for full description of fitting parameters. Note: at  $\text{N/P} = 4$  lipopolyplexes contain a polycation concentration of  $0.06 \text{ mM}$ .

## Conclusions

We studied how biological nucleophiles can be used to trigger intracellular DNA release from charge-reversing polycations, leading to improved transfection and reduced cytotoxicity. The cationic-to-neutral transition is rapidly triggered with glutathione (a thiol), while amino acids (primary amines) slowly deionize the polymer. Micelle, polyplex and lipopolyplex type pDNA complexes were prepared, with lipopolyplexes found to effectively transfect CHO cells. These lipopolyplexes yielded up to 10 times more transfection than analogous non-responsive lipopolyplexes and showed reduced cytotoxicity. This improved transfection was achieved despite a similar cellular internalisation of pDNA for both treatments, indicating the importance of polymer decationization and pDNA release. To understand this behaviour, we studied the charge-reversing process in model extracellular (amino acid rich cell culture media) and intracellular ( $1 \text{ mM}$  glutathione) conditions. Polyplexes were found to deionize and release their pDNA cargo 16 times faster (within 15 minutes) in model intracellular conditions

compared to extracellular conditions. We thus hypothesise that the nucleophile triggered decationization, which is significantly accelerated in the intracellular space, leads to pDNA release for improved transfection and reduced cytotoxicity.

## Supporting Information

Additional experimental details and methods, including  $^1\text{H}$  NMR spectra, GPC chromatograms, TEM micrographs, CLSM images and DLS data.

## Author contributions

**R.L.:** Conceptualisation, Investigation, Writing – Original Draft **A.M.:** Investigation, Writing – Review & Editing **B.K.:** Investigation (DVP and Me-Az synthesis) **P.B.:** Resources, Supervision, Writing – Review & Editing **R.E.:** Conceptualisation, Resources, Supervision, Writing – Review & Editing

## Conflicts of interest

There are no conflicts of interest.

## Acknowledgments

The authors acknowledge financial support by the European Research Council (ERC Consolidator Grant 726381). A.M and P.E.B gratefully acknowledge the funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement no. 819424). We also thank P. ten Dijke and P. Mehta (Leiden University Medical Center) for provision of plasmid and assistance in preliminary flow cytometry analysis, K. David (TU Delft) for plasmid cloning, C. Danelon and A. Sierra (Department of Bionanoscience, TU Delft) for access to flow cytometer and S. Brouns (Department of Bionanoscience, TU Delft) for access to gel electrophoresis and microplate readers.

## References

1. S. M. Alnasser, *Gene*, 2021, **769**, 145246.
2. S. Uchida and K. Kataoka, *J. Biomed. Mater. Res. A*, 2019, **107**, 978-990.



3. K. Muhammad, J. Zhao, B. Gao and Y. Feng, *J. Mater. Chem. B*, 2020, **8**, 9621-9641.
4. R. Kumar, C. F. Santa Chalarca, M. R. Bockman, C. V. Bruggen, C. J. Grimme, R. J. Dalal, M. G. Hanson, J. K. Hexum and T. M. Reineke, *Chem. Rev.*, 2021, **121**, 11527-11652.
5. K. Dutta, R. Das, J. Medeiros, P. Kanjilal and S. Thayumanavan, *Adv. Funct. Mater.*, 2021, **31**, 2011103.
6. H. Cabral, K. Miyata, K. Osada and K. Kataoka, *Chem. Rev.*, 2018, **118**, 6844-6892.
7. X. Liu, J. Xiang, D. Zhu, L. Jiang, Z. Zhou, J. Tang, X. Liu, Y. Huang and Y. Shen, *Adv. Mater.*, 2016, **28**, 1743-1752.
8. M. Rezaee, R. K. Oskuee, H. Nassirli and B. Malaekheh-Nikouei, *J. Control. Release*, 2016, **236**, 1-14.
9. A. Ewe and A. Aigner, *Methods Mol Biol*, 2016, **1445**, 187-200.
10. H. Pollard, J.-S. Remy, G. Loussouarn, S. Demolombe, J.-P. Behr and D. Escande, *J. Biol. Chem.*, 1998, **273**, 7507-7511.
11. B. Shi, M. Zheng, W. Tao, R. Chung, D. Jin, D. Ghaffari and O. C. Farokhzad, *Biomacromolecules*, 2017, **18**, 2231-2246.
12. W. Guo and R. J. Lee, *Biosci. Rep.*, 2000, **20**, 419-432.
13. K. D. Murray, C. J. Etheridge, S. I. Shah, D. A. Matthews, W. Russell, H. M. D. Gurling and A. D. Miller, *Gene Ther.*, 2001, **8**, 453-460.
14. J. Zabner, A. J. Fasbender, T. Moninger, K. A. Poellinger and M. J. Welsh, *J. Biol. Chem.*, 1995, **270**, 18997-19007.
15. C. J. McKinlay, J. R. Vargas, T. R. Blake, J. W. Hardy, M. Kanada, C. H. Contag, P. A. Wender and R. M. Waymouth, *Proc. Natl. Acad. Sci.*, 2017, **114**, E448-E456.
16. N. L. Benner, R. L. McClellan, C. R. Turlington, O. A. W. Haabeth, R. M. Waymouth and P. A. Wender, *J. Am. Chem. Soc.*, 2019, **141**, 8416-8421.
17. N. L. Benner, K. E. Near, M. H. Bachmann, C. H. Contag, R. M. Waymouth and P. A. Wender, *Biomacromolecules*, 2018, **19**, 2812-2824.
18. S. Ros, J. S. Freitag, D. M. Smith and H. D. H. Stöver, *ACS Omega*, 2020, **5**, 9114-9122.
19. D. Zhu, H. Yan, X. Liu, J. Xiang, Z. Zhou, J. Tang, X. Liu and Y. Shen, *Adv. Funct. Mater.*, 2017, **27**, 1606826.
20. N. Qiu, J. Gao, Q. Liu, J. Wang and Y. Shen, *Biomacromolecules*, 2018, **19**, 2308-2319.
21. G. Wang, S. Chen, N. Qiu, B. Wu, D. Zhu, Z. Zhou, Y. Piao, J. Tang and Y. Shen, *Nano Today*, 2021, **39**, 101215.
22. B. Klemm, R. W. Lewis, I. Piergentili and R. Eelkema, *Nat. Commun.*, 2022, **13**, 6242.
23. B. Wu, R. W. Lewis, G. Li, Y. Gao, B. Fan, B. Klemm, J. Huang, J. Wang, M. A. Cohen Stuart and R. Eelkema, *Chem. Sci.*, 2023, DOI: 10.1039/D2SC06935K.
24. R. W. Lewis, B. Klemm, M. Macchione and R. Eelkema, *Chem. Sci.*, 2022, **13**, 4533-4544.
25. H. Godel, T. Graser, P. Földi, P. Pfaender and P. Fürst, *J. Chromatogr. A*, 1984, **297**, 49-61.
26. W. H. Stein and S. Moore, *J. Biol. Chem.*, 1954, **211**, 915-926.
27. K. A. Piez and H. Eagle, *J. Biol. Chem.*, 1958, **231**, 533-545.
28. J. Bergström, P. Fürst, L. O. Norée and E. Vinnars, *J. Appl. Physiol.*, 1974, **36**, 693-697.
29. H. J. Forman, H. Zhang and A. Rinna, *Mol Aspects Med*, 2009, **30**, 1-12.
30. H. T. Ho, M. E. Levere, S. Pascual, V. Montembault, J.-C. Soutif and L. Fontaine, *J. Polym. Sci., Part A: Polym. Chem.*, 2012, **50**, 1657-1661.
31. W. Guo, A. Umar, H. Algadi, H. Albargi, A. A. Ibrahim, K. Cui, L. Wang, M. Pei and Y. Wang, *Microchem. J.*, 2021, **169**, 106548.

32. P. Klassen, P. Fürst, C. Schulz, M. Mazariegos and N. W. Solomons, *Am. J. Clin. Nutr.*, 2001, **73**, 647-652.
33. S. Mochizuki, N. Kanegae, K. Nishina, Y. Kamikawa, K. Koiwai, H. Masunaga and K. Sakurai, *Biochim. Biophys. Acta*, 2013, **1828**, 412-418.
34. K. S. Lee, H. K. Kim, H. S. Moon, Y. S. Hong, J. H. Kang, D. J. Kim and J. G. Park, *Korean J Intern Med*, 1992, **7**, 111-117.
35. A. B. Moshnikova, V. N. Afanasyev, O. V. Proussakova, S. Chernyshov, V. Gogvadze and I. P. Beletsky, *Cell. Mol. Life Sci.*, 2006, **63**, 229-234.
36. J. Boekhoven, W. E. Hendriksen, G. J. M. Koper, R. Eelkema and J. H. van Esch, *Science*, 2015, **349**, 1075-1079.
37. M. Tena-Solsona, B. Rieß, R. K. Grötsch, F. C. Löhrer, C. Wanzke, B. Käsdorf, A. R. Bausch, P. Müller-Buschbaum, O. Lieleg and J. Boekhoven, *Nat. Commun.*, 2017, **8**, 15895.
38. S. Borsley, D. A. Leigh and B. M. W. Roberts, *Nature Chemistry*, 2022, **14**, 728-738.